FDA calendar · June 2024 · built from SEC filings

PDUFA dates June 2024: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

1 PDUFA date fell in June 2024: ZUSDURI (Jun 2024). The FDA calendar also recorded 56 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in June 2024

1 PDUFA target action date in June 2024, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
PDUFA dateCompanyTickerDrugIndicationSource
Jun 2024UroGen Pharma Ltd.URGNZUSDURI (mitomycin)SEC 8-K Exhibit 99.1, filed 2025-01-14

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

June 2024: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Jun 2024Month disclosedBLINCYTO® (blinatumomab)AMGNFDA approval—ApprovedSEC Form 10-K
Jun 2024Month disclosedEPKINLYGMABFDA approval—ApprovedSEC 8-K Exhibit 99.1
Jun 2024Month disclosedTEPKINLY (epcoritamab)GMABFDA approvalwith relapsed or refractory FLApprovedSEC 8-K Exhibit 99.1
Jun 2024Month disclosed—LGNDFDA approval—ApprovedSEC 8-K Exhibit 99.1
Jun 2024Month disclosedChenodalMIRMNDA/BLA acceptedCTX, knownCompletedSEC Form 10-Q
Jun 2024Month disclosed—RCKTComplete Response Letter—CRL issuedSEC Form 10-Q
June 6, 2024RYTELO (imetelstat)GERNFDA approvalTo treat low- to intermediate-1 risk myelodysplastic syndromesApprovedSEC 8-K Exhibit 99.1
June 7, 2024KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
June 7, 2024IBTROZI (taletrectinib)NUVBNDA/BLA submission—CompletedSEC Form 10-K
June 10, 2024Kevzara (sarilumab)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
June 12, 2024Farxiga (dapagliflozin)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
June 12, 2024Xigduo Xr (dapagliflozin; metformin hydrochloride)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
June 12, 2024Retevmo (selpercatinib)LLYLabel expansion—ApprovedopenFDA Drugs@FDA
June 13, 2024AUGTYRO (repotrectinib)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
June 14, 2024BLINCYTO® (blinatumomab)AMGNLabel expansion—ApprovedopenFDA Drugs@FDA
June 14, 2024Imfinzi® (durvalumab)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
June 14, 2024rocketRCKTComplete Response Letter—CRL issuedFDA Complete Response Letters
June 18, 2024Vyalev (foscarbidopa; foslevodopa)ABBVComplete Response Letter—CRL issuedFDA Complete Response Letters
June 18, 2024Skyrizi (risankizumab-rzaa)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
June 21, 2024VYVGART (efgartigimod)ARGXFDA approval—ApprovedSEC 8-K Exhibit 99.1
June 21, 2024Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)ARGXLabel expansion—ApprovedopenFDA Drugs@FDA
June 21, 2024Krazati (adagrasib)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
June 21, 2024WAKIX® (pitolisant)HRMYLabel expansionEDS in pediatric patients six years of age and older with narcolepsyApprovedSEC Form 10-Q
June 21, 2024Sirturo (bedaquiline fumarate)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
June 26, 2024Epkinly (epcoritamab-bysp)GMABLabel expansion—ApprovedopenFDA Drugs@FDA
June 26, 2024Ohtuvayre (ensifentrine)MRKFDA approvalTo treat chronic obstructive pulmonary diseaseApprovedFDA Novel Drug Approvals
June 26, 2024Adakveo (crizanlizumab-tmca)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
June 26, 2024Vancomycin Hydrochloride (vancomycin)VTRSLabel expansion—ApprovedopenFDA Drugs@FDA
June 28, 2024CER-1236CERONDA/BLA submission—Completedsec_s1
June 30, 2024Vafseo® (vadadustat)AKBAFDA approval—ApprovedSEC Form 10-K

June 2024: dated readouts

DateDrugCompanyEventIndicationStatusSource
Jun 2024Month disclosed—ABBVTopline readout—PositiveSEC Form 10-K
Jun 2024Month disclosedAMVUTTRA® (vutrisiran)ALNYTopline readoutATTR amyloidosis with cardiomyopathyPositiveSEC Form 10-K
Jun 2024Month disclosedUPLIZNA® (inebilizumab)AMGNTopline readoutImmunoglobulin G4-related diseasePositiveSEC Form 10-K
Jun 2024Month disclosedAnaphylm™ (dibutepinephrine)AQSTTopline readout—PositiveSEC Form 10-Q
Jun 2024Month disclosedCardiolRx™ (cardiolrx)CRDLTopline readout—PositiveSEC 8-K Exhibit 99.1
Jun 2024Month disclosed—CRDLTopline readout—PositiveSEC 8-K Exhibit 99.1
Jun 2024Month disclosedCRD-38CRDLTopline readout—PositiveSEC 8-K Exhibit 99.1
Jun 2024Month discloseditolizumab (EQ001)EQTopline readoutalopecia areata, or AA, and in June 2024, wePositiveSEC Form 10-Q
Jun 2024Month disclosedaleniglipron (GSBR-1290)GPCRTopline readout—Met primary endpointSEC Form 10-Q
Jun 2024Month disclosedimatinib (IKT-001)IKTTopline readout—Missed primary endpointSEC Form 10-K
Jun 2024Month disclosed—MIRMInterim readout—Met primary endpointSEC 8-K Exhibit 99.1
Jun 2024Month disclosedlicaminlimab (OCS-02)OCSTopline readoutsigns and symptoms of moderate to severe DEDPositiveSEC 8-K Exhibit 99.1
Jun 2024Month discloseddivesiran (SLN124)SLNInterim readout—PositiveSEC 8-K Exhibit 99.1
Jun 2024Month disclosed—SVRATopline readout—Positivesec_424b
June 25, 2024IGALMI® (dexmedetomidine)BTAIQTopline readout—PositiveSEC Form 10-Q

June 2024: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Jun 2024Month disclosedclofazimine (MNKD-101)MNKDTrial start—CompletedSEC Form 10-K
Jun 2024Month disclosedDB-1305BNTXTrial start—CompletedSEC 8-K Exhibit 99.1
Jun 2024Month disclosedVS-7375VSTMTrial start—CompletedSEC Form 8-K
Jun 2024Month disclosedLTSE-2578GPCRTrial startidiopathic pulmonary fibrosisCompletedSEC Form 10-Q
Jun 2024Month disclosedHMPL-506HCMTrial starthematological malignanciesCompletedSEC Form 10-K
Jun 2024Month disclosedTH103KLRSTrial start—CompletedSEC 8-K Exhibit 99.1
Jun 2024Month disclosedKPL-387KNSATrial start—CompletedSEC Form 10-Q
Jun 2024Month disclosedKEYTRUDA® (pembrolizumab)MRNATrial start—CompletedSEC Form 10-K
Jun 2024Month disclosedSPY001SYRETrial start—CompletedSEC Form 10-Q
Jun 2024Month disclosedTRB-051TRXBTrial start—Completedsec_424b
Jun 2024Month disclosedIPH6501IPHATrial start—CompletedSEC 8-K Exhibit 99.1

2 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps June 2024. They are on each drug page and in the calendar API.

Questions

What PDUFA dates are in June 2024?

1 PDUFA date fell in June 2024: ZUSDURI (Jun 2024). The FDA calendar also recorded 56 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.